Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-CAR T-cell Delivery Program
- Development stage
- Preclinical
- Lead developer
- Nanite Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Silencing → Gene Therapies, Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous
01
Overview
Nanite Therapeutics' CD19-CAR T-cell Delivery Program is a preclinical gene therapy approach that utilizes the company's proprietary SAYER™ platform. The SAYER platform employs AI-designed polymer nanoparticles (PNPs) to deliver a CD19 chimeric antigen receptor (CAR) transgene directly to T cells. This method aims to generate CD19-directed CAR-T cells, potentially offering an alternative to traditional viral vector-based delivery systems for treating B-cell malignancies. The program is being developed in collaboration with an undisclosed partner and focuses on leveraging non-viral delivery to improve the efficiency and safety of CAR-T cell generation.
- Other names
- Nanite CD19-CAR PNPSAYER CD19-CAR
02
Targets
CD28 (Cluster of Differentiation 28)CD3 (T-cell surface glycoprotein CD3)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on CD19-CAR T-cell Delivery Program.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19-CAR T-cell Delivery Program.